Brand licensor or exclusive supplier

Hong Kong IPO disclosure precedents · 13 companies, 13 items

Products sold bear a third party's brand under licence (often via a joint venture with the brand owner) or are exclusively supplied by a collaboration partner who controls supply, quality, registration and IP.

2026-08-31Application Proof
Guangxi Yuchai Marine and Genset Power Co., Ltd.广西玉柴船电动力股份有限公司

MTU Yuchai is a 50–50 joint venture established pursuant to the joint venture agreement between our parent and immediate Controlling Shareholder GYMCL and Rolls-Royce, a subsidiary of Rolls-Royce Power Systems AG, in 2017 for the production, under license from Rolls-Royce and subject to the terms and conditions of such license, of mtu branded diesel engines in China.

Business · p. 155

For FY2023, FY2024, FY2025, 1H2025 and 1H2026, revenue generated by Yuchai Deyou amounted to RMB200.6 million, RMB259.2 million, RMB307.8 million, RMB189.7 million and RMB215.9 million, representing 6.2%, 6.5%, 5.0%, 6.3% and 4.8% of our total revenue, respectively.

Business · p. 156

Through this dual-brand strategy, we are able to address the differentiated needs and preferences of customers.

Business · p. 147
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-28Application Proof
Betta Pharmaceuticals Co., Ltd.贝达药业股份有限公司

BioRay is responsible for supplying the Trastuzumab Product, ensuring quality control, and supporting required regulatory matters.

Business · p. 175

Healthgen is responsible for supply, documentation, regulatory filings, and quality control of the Product.

Business · p. 176

Gensciences or its affiliates will supply the product to us or our designated entities on an exclusive basis for sales in the Territory.

Business · p. 180
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-07Application Proof
Suzhou Genhouse Bio Co., Ltd.勤浩医药(苏州)股份有限公司

Garsorasib used in the combination therapy clinical trial is supplied by Zhengda Tianqing for free under the combination therapy development agreement.

Summary · p. 4

Osimertinib used in the combination therapy clinical trial is supplied by AstraZeneca for free under the clinical supply collaboration agreement.

Summary · p. 4

Notwithstanding these, our IP Legal Advisers and Directors are of the view, and the Sole Sponsor concur, that we have full and independent R&D capabilities to continue the development and commercialisation of GH21 without reliance on our partners

Business · p. 164
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-29Application Proof

For the years ended December 31, 2023, 2024 and 2025, our revenue generated from sales of channel exclusive products under our general self-operated business amounted to RMB60.2 million, RMB57.9 million and RMB184.0 million, respectively, representing 5.6%, 5.6% and 13.1%, respectively, of our total revenue during the same years.

Business · p. 147

During the term, the brands and manufacturers undertake not to directly or indirectly appoint other distributors, nor engage in the sale of the authorized brands or products through other channels.

Business · p. 148

We are able to obtain designated channel arrangements from family care and nutrition product brands and manufacturers mainly based on (i) our leading position and solid reputation in China’s family care and nutrition product industry in lower-tier market, which can enhance the influence of their brands along the distribution process, (ii) the vast offline retail network we organized that deeply penetrates into counties and villages in China, providing efficient distribution channels for their products, and (iii) our dedicated category operation team and effective retail sales monitoring to ensure the appropriate distribution of their products.

Business · p. 148
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-06-18Prospectus
Alebund Pharmaceuticals (Jiangsu) Limited礼邦医药(江苏)股份有限公司09637.HK

Roche shall supply Mircera^®^ to us pursuant to an annual purchase schedule and price terms provided in the Roche Agreement.

Business · p. 186

Roche shall obtain and maintain the drug registration certificate and its appendices of Mircera^®^ in China at its own expense.

Business · p. 186

The Roche Agreement shall remain in force for ten years, unless terminated earlier, and shall be automatically renewed for another five-year period, unless either party notices the other party in writing of its intent not to renew in advance.

Business · p. 186
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-29Application Proof
Genuine Biotech Limited真实生物科技有限公司

Sintilimab will be the exclusively designated PD-1 agent in our future standard-of-care treatment regimens.

Business · p. 164

(2) Innovent shall supply Innovent Compound, while Henan Genuine shall supply azvudine for the R&D activities of the azvudine + anti-PD-1 combination therapy.

Business · p. 190

Innovent has the right to immediately terminate the R&D plan and all related R&D activities upon written notification to Henan Genuine if any R&D activities conducted in accordance with this plan raise safety concerns.

Business · p. 190
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-05-26Application Proof
HLA GROUP CORP., LTD.海澜之家集团股份有限公司

We operate the Adidas Future City Concept (“FCC”) business exclusively in Chinese mainland and hold the HEAD apparel license for Chinese mainland, Hong Kong, Macau and Taiwan.

Financial Information · p. 180

Revenue from our international sports brands had increased rapidly throughout the Track Record Period, amounting to RMB20.6 million, RMB1,070.2 million and RMB1,617.7 million in 2023, 2024 and 2025, respectively.

Financial Information · p. 180
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-04-27Application Proof
Guangzhou Ruoyuchen Technology Co., Ltd.广州若羽臣科技股份有限公司

Our revenue growth and overall business success depend significantly on our ability to maintain stable relationships with existing brand partners and attract new brand partners.

Financial Information · p. 188

During the Track Record Period, we derived a substantial portion of our revenue from providing brand management and e-commerce operation solutions to our brand partners.

Financial Information · p. 188

As of the Latest Practicable Date, we were in collaboration with 37 brand partners, five of which had worked with us for over five years.

Financial Information · p. 188
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-03-31Application Proof
Beijing Data Intelink Technology Co., Ltd.北京数聚智连科技股份有限公司

For the years ended December 31, 2023, 2024 and 2025, RMB820.6 million, RMB762.8 million and RMB900.7 million, or approximately 51.5%, 55.3% and 56.0% of our total revenue for the respective years were related to the top five brand partners in terms of revenue contribution we served in each year, and RMB286.6 million, RMB240.0 million and RMB273.1 million, or approximately 18.0%, 17.4% and 17.0% of our total revenue for the respective years were related to the largest brand partners in terms of revenue contribution.

Business · p. 124

We believe we have established long-term, mutually beneficial relationships with the brands we serve by consistently delivering value, and have maintained cooperative relationships with many of these brands for several years.

Business · p. 124

Our performance is closely linked to the strategic decisions of our brand partners. Changes in global or regional strategies—such as market exits, ownership changes, or shifts in channel priorities—may affect the scope and scale of our cooperation.

Financial Information · p. 180
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-01-30Prospectus
Montage Technology Co., Ltd.澜起科技股份有限公司06809.HK

We collaborate with Intel for our Jintide products, which accounted for approximately 7.7% and 5.4% of our total revenue in 2024 and the nine months ended September 30, 2025, respectively.

Business · p. 208

We purchase Intel’s standard CPU cores on an arm’s length basis and consolidate them with our proprietary PrC (Pre-Check) or DSC (dynamic security check) features.

Business · p. 208

Therefore, we are not dependent on Intel.

Business · p. 208
The company's explanation, the adviser's view and the page in the filing: see Matters
2025-11-27Prospectus
Guangzhou Xiao Noodles Catering Management Co., Ltd.广州遇见小面餐饮股份有限公司02408.HK

We have engaged the Supply Chain Service Group for the procurement of food ingredients since 2019.

Business · p. 213

Our Directors are of the view that we are not materially reliant on the Supply Chain Service Group as there are readily available alternative suppliers of similar services in the market and we maintain a pool of alternative supplier candidates, allowing us to procure similar services from other suppliers in the market without materially and adversely affecting our business and results of operations should we decide to do so.

Business · p. 215
The company's explanation, the adviser's view and the page in the filing: see Matters
2025-08-25Prospectus
AUX ELECTRIC CO., LTD.奥克斯电气有限公司02580.HK

We collaborate with Panasonic regarding the research and production of compressor, which is a core component for our products.

Summary · p. 18

As the essential components of our air conditioners, this initiative will allow us to establish a robust foundation for delivering high-quality products while effectively mitigating risks associated with material supply uncertainties.

Business · p. 226
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-03-16Prospectus
DPC Dash Ltd达势股份有限公司01405.HK

We have the exclusive right to set up and operate Domino’s Pizza stores, as well as to use and license the Domino’s Pizza and associated trademarks in the operation of pizza stores in the China mainland, the Hong Kong Special Administrative Region of China and the Macau Special Administrative Region of China (the “Territory”).

Business · p. 217

The initial term of the Master Franchise Agreement will expire on June 1, 2027.

Business · p. 217

We do not foresee any material impediment to meeting these growth targets for the remainder of the term of the Master Franchise Agreement, which requires that we maintain 1,000 stores by the end of 2026.

Business · p. 218
The company's explanation, the adviser's view and the page in the filing: see Matters

Tell us